


Product Data Sheet

Tasquinimod

Cat. No.:	A3860
CAS No.:	254964-60-8
Formula:	C ₂₀ H ₁₇ F ₃ N ₂ O ₄
M.Wt:	406.36
Synonyms:	ABR-215050; ABR215050; ABR 215050
Target:	DNA Damage/DNA Repair
Pathway:	HDAC
Storage:	Store at -20°C



Solvent & Solubility

insoluble in H₂O; ≥20.32 mg/mL in DMSO; ≥4.75 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	Concentration			
	1 mM	2.4609 mL	12.3044 mL	24.6087 mL
	5 mM	0.4922 mL	2.4609 mL	4.9217 mL
	10 mM	0.2461 mL	1.2304 mL	2.4609 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Antiangiogenic and antineoplastic agent

IC₅₀ & Target

Cell Viability Assay

In Vitro

Cell Line:	LNCaP cells
Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	24 h; 50 μM

	Applications:	Generated microarray data based on four separate biological replicates showed a drug-induced effect of 50µM tasquinimod on gene expression in LNCaP cells when cultured in vitro for 24 h. The expression data achieved by RT-PCR were consistent with the microarray analysis data with a significant up-regulation of THBS1, GDF15 and CYP1A1 whereas CXCR4 and AGER1 did not change expression significantly.
In Vivo	Animal experiment	
	Animal models:	Male athymic Nude BALB/c mice (age 8 weeks)
	Dosage form:	10 mg/kg /day; oral taken
	Applications:	To investigate whether an early treatment could inhibit tumor establishment in addition to the previously shown effects on tumor growth, treatment was initiated directly at subcutaneous inoculation of LNCaP cells and compared to treatment starting 1 week after inoculation, when tumor growth already was established. In the control group the take rate was 100%. By direct treatment the tumor take rate was decreased to 12.5 % by tasquinimod (10 mg/kg/day) compared to 87.5% in the group treated from 1 week after inoculation (P<0.01). In addition, tasquinimod decreased the size of established tumors when treated from day 7.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

See more customer validations on www.apexbt.com.

References

- [1] Olsson A, Björk A, Vallon-Christersson J, et al. Research Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors[J]. 2010.
- [2] Jennbacken K, Welen K, Olsson A, et al. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline - 3 - carboxamide tasquinimod (ABR - 215050)[J]. The Prostate, 2012, 72(8): 913-924.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.



Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

